Specialty Pharmacy

Approval sought for Imbruvica combination for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Marc O'Connor, chief operating officer of Curant Health, discusses counseling patients on a therapeutic regimen for IBD.

Multiple myeloma comorbidities may contribute to the development of pulmonary hypertension.

ABT-494 is a novel selective Janus Kinase 1 inhibitor acting against enzymes implicated in inflammatory diseases and some types of cancer.

Patients with a family history of Lynch syndrome should be presented the option of risk prediction modeling.

How treatment with Harvoni changed the life of a patient infected with HCV.

Clostridium sporogenes bacteria able to eradicate colon cancer tumor cells.

Top news of the week in cancer drug development.

Statins may influence alterations in the airways of asthmatics during restructuring.

Intestinal microbiome found to influence MS disease emergence and progression.

Beneficiaries increasingly choosing health care plans that include some cost-sharing reduction provisions for co-pays and coinsurance.

Positive mood throughout daily life linked to less pain and fewer RA-related restrictions.

Modified version of Adynovate lasts longer in the blood for less frequent injections.

HIV drug Tenofovir may carry a risk of nephrotoxicity.

Top stories of the week on Specialty Pharmacy Times.

Osimertinib (Tagrisso) is a once daily tablet for patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

Hormone treatment may prove to be effective alternative option for patients with invasive lobular carcinoma.

MS cognitive screening tool able to predict actual functional performance.

Treatment with sarilumab improves RA signs, symptoms, and physical function.

Patients simultaneously registering at multiple centers had higher transplant rates, lower death rates waiting for a transplant, and greater income.

Ixekizumab found to improve skin clearance of plaque psoriasis and reduced disability when performing certain physical functions.

Questions still persist regarding immunologic mechanisms of MS treatments and vitamin D.

Side effects, familial support and liver condition among factors that influence hepatitis C treatment decisions.

Initiative does not prohibit the purchase or sale of private coverage duplicating the public plan.

The FDA has accepted for review Amgen's new drug application for etelcalcetide to treat secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis.

Pharmacy interventions for patients taking new medications can improve adherence, reduce health care costs, and improve outcomes.

Cosentyx found to maintain improvements in joint and skin disease, physical function, and quality of life in PsA patients.

Patients with cancer see a decline in employment, hours worked, individual income, and total family income following diagnosis.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the development of medical marijuana within the specialty space.

HCV drug combination may cut treatment time by 75%.